Please assess the completion status of the following clinical trial:

Trial Title: Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Postmenopausal state, defines as natural amenorrhea for at least 12 months.~2. Age; females 52-65 years, males: 40-65 years.~3. Type 2 diabetes based on fasting plasma glucose or 2-hr glucose after an OGTT.~4. Diabetes duration less than 5 years.~Exclusion Criteria:~1. Patients with concurrent use of nitrates or NO donors, history of heart or cerebrovascular disease, cardiac failure (stages NYHA II-IV), uncontrolled hypertension (\> 160/100 mm Hg), significant diabetic complications, and inadequate glycemic control (HbA1c \> 7%, ref value 3.5-5.3%)~2. Patients on glitazones, insulin, beta-blockers, ACE-inhibitors and corticosteroids

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): A single dose of placebo is administered 30 min before a mixed meal.
- Tadalafil (Type: ACTIVE_COMPARATOR): A single dose of tadalafil 20 mg is administered 30 min before a mixed meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).